PortmanDJ, GassML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause, 2014; 21:1063–1068.
2.
Mac BrideMB, RhodesDB, ShusterLT. Vulvovaginal atrophy. Mayo Clin Proc, 2010; 85:87–94.
3.
FaubionSS, SoodR, KapoorE. Genitourinary syndrome of menopause: Management strategies for the clinician. Mayo Clin Proc, 2017; 92:1842–1849.
4.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause, 2013; 20:888–902.
5.
PerinoA, CalligaroA, ForlaniF, et al.Vulvo-vaginal atrophy: A new treatment modality using thermo-ablative fractional CO2 laser. Maturitas, 2015; 80:296–301.
6.
SalvatoreS, NappiRE, ZerbinatiN, et al.A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: A pilot study. Climacteric, 2014; 17:363–369.
7.
SokolER, KarramMM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause, 2016; 23:1102–1107.
8.
KwanKW, ChlebowskiRT. Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin Breast Cancer, 2009; 9:219–224.
9.
SchoverLR, BaumGP, FusonLA, BrewsterA, Melhem-BertrandtA. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors. J Sex Med, 2014; 11:3102–3111.
10.
MarinoJL, SaundersCM, EmeryLI, GreenH, DohertyDA, HickeyM. How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer?. Menopause, 2016; 23:1000–1008.
11.
LeiblumSR, KoochakiPE, RodenbergCA, BartonIP, RosenRC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause, 2006; 13:46–56.
12.
McCabeMP, SharlipID, LewisR, et al.Incidence and prevalence of sexual dysfunction in women and men: A consensus statement from the Fourth International Consultation on Sexual medicine 2015. J Sex Med, 2016; 13:144–152.
13.
ParishSJ, HahnSR. Hypoactive sexual desire disorder: A review of epidemiology, biopsychology, diagnosis, and treatment. Sex Med Rev, 2016; 4:103–120.
14.
KingsbergSA. Attitudinal survey of women living with low sexual desire. J Womens Health (Larchmt). 2014; 23:1888–1906.
15.
ClaytonAH, GoldfischerER, GoldsteinI, DeRogatisL, Lewis-D'AgostinoDJ, PykeR. Validation of the decreased sexual desire screener (DSDS): A brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med, 2009; 6:730–738.
16.
ParishSJ, GolsteinAT, GoldsteinSW, et al.Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions-Part II. J Sex Med, 2016; 13:1888–1906.
17.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association, 2013. Available at: http://dsm.psychiatryonline.org/book.aspx?bookid=556
18.
DavisonSL, BellRJ, LaChinaM, et al.The relationship between self-reported sexual satisfaction and general well-being in women. J Sex Med, 2009; 6:2690–2697.
19.
BorsiniF, EvansK, JasonK, RohdeF, et al.Pharmacology of flibanserin. CNS Drug Rev, 2002; 8:117–142.
20.
MarazzitiD, PalegoL, GiromellaA, et al.Regiondependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain. Int J Neuropsychopharmacol, 2002; 5:131–140.
21.
AllersKA, DremencovE, CeciA, et al.Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: A microdialysis study. J Sex Med, 2010; 7:1757–1767.
22.
StahlSM, SommerB, AllersKA. Multifunctional pharmacology of flibanserin: Possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med, 2011; 8:15–27.
23.
JoffeH, ChangC, SewellC, et al.FDA approval of flibanserin—Treating hypoactive sexual desire disorder. N Engl J Med, 2016; 374:101–104.
24.
RatnerC, EttrupA, BueterM, et al.Cerebral markers of the serotonergic system in rat models of obesity and after Roux-en-Y gastric bypass. Obesity (Silver Spring), 2012; 20:2133–2141.
25.
BerglundED, LiuC, SohnJW, et al.Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis. J Clin Invest, 2013; 123:5061–5070.
26.
BlumenthalSR, CastroVM, ClementsCC, et al.An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry, 2014; 71:889–896.
27.
Belviq (lorcaserin hydrochloride) tablets, for oral use CIV [package insert]. Zofingen: Arena Pharmaceuticals GmbH, 2014.
